Study
| Multi-center, open lavel study (eNRGy) |
| NRG1 fusion positive NSCLC (n=64) and pancreatic adenocarcinoma (n=30) with disease progression after standard therapy |
Efficacy
| ORR: 33% [22%-46%] in NSCLC; 40% [23% – 59%] in pancreatic cancer |
| Pts with DoR > 6 mos: 43% in NSCLC, 67% in pancreatic cancer |
Safety
| Grade >=3 AEs: Dyspnea (5%), diarrhea (5%), nausea (5%), hemorrhage (5%) |
Zenotuzumab Label. FDA Database accessed 2024-12-06
FDA Zenocutuzumab Product Label – BLA761352
http://www.ncbi.nlm.nih.gov/pubmed/0
Reviewed by Ulas D. Bayraktar, MD on Dec 6, 2024
